| Completed | A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of Amoxicillin NCT07308041 | Cinclus Pharma Holding AB | Phase 1 |
| Recruiting | Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabete NCT07098663 | Mankind Pharma Limited | Phase 2 |
| Completed | A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults NCT07226362 | Aspeya Switzerland SA | Phase 1 |
| Completed | SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants NCT06453824 | MDI Therapeutics, Inc. | Phase 1 |
| Completed | Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics/-Dynamics of AK1967 (Procizumab) NCT06331884 | 4TEEN4 Pharmaceuticals GmbH | Phase 1 |
| Completed | A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers NCT06181760 | Island Pharmaceuticals | Phase 1 |
| Active Not Recruiting | Evaluating the Safety, Tolerability, and Pharmacokinetics of DF-003 in Healthy Subjects NCT05997641 | Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) | Phase 1 |
| Terminated | A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 NCT06000891 | Zealand Pharma | Phase 1 |
| Unknown | Phase 1 Clinical Study of JMKX003142 Tablets NCT06079541 | Jemincare | Phase 1 |
| Unknown | Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects NCT05907382 | Jemincare | Phase 1 |
| Completed | Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy Volun NCT05451667 | Yuejia Pharmaceuticals (USA), Inc. | Phase 1 |
| Unknown | A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate NCT05469854 | Cinclus Pharma AG | Phase 1 |
| Completed | Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants NCT05431634 | Alumis Inc | Phase 1 |
| Completed | A Phase I Pharmacokinetics Study for KT07 Capsule NCT05223660 | Yiling Pharmaceutical Inc. | Phase 1 |
| Completed | Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin NCT03853421 | Modus Therapeutics AB | Phase 1 |
| Completed | A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects NCT03809052 | Galecto Biotech AB | Phase 1 |
| Completed | Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers NCT03817346 | Gabather AB | Phase 1 |
| Completed | Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Tr NCT03702231 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Ki NCT03685708 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Terminated | PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD NCT03307512 | Dance Biopharm Inc. | Phase 2 |
| Completed | DP13 SAD & MAD in Healthy Male Subjects NCT03046589 | Damian Pharma AG | Phase 1 |
| Completed | Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Toler NCT01895946 | AstraZeneca | Phase 1 |
| Completed | Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of K-312 in Healthy Adult Volunteers NCT01952548 | Kowa Research Institute, Inc. | Phase 1 |
| Completed | Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer. NCT01692262 | AstraZeneca | Phase 1 |
| Completed | Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin NCT01907867 | MerLion Pharmaceuticals GmbH | Phase 1 |
| Completed | Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Sc NCT01226316 | AstraZeneca | Phase 1 |
| Completed | Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy NCT02029482 | Actelion | Phase 1 |